Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

Authors: Koikawa, Kazuhiro; Kibe, Shin; Suizu, Futoshi; Sekino, Nobufumi; Kim, Nami; Manz, Theresa D; Pinch, Benika J; Akshinthala, Dipikaa; Verma, Ana; Gaglia, Giorgio; Nezu, Yutaka; Ke, Shizhong; Qiu, Chenxi; Ohuchida, Kenoki; Oda, Yoshinao; Lee, Tae Ho; Wegiel, Babara; Clohessy, John G; London, Nir; Santagata, Sandro; Wulf, Gerburg M; Hidalgo, Manuel; Muthuswamy, Senthil K; Nakamura, Masafumi; Gray, Nathanael S; Zhou, Xiao Zhen; Lu, Kun Ping

Published In Cell, (2021 Sep 02)

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and immunosuppressive tumor microenvironment (TME). Unique proline isomerase Pin1 regulates multiple cancer pathways, but its role in the TME and cancer immunotherapy is unknown. Here, we find that Pin1 is overexpressed both in cancer cells and cancer-associated fibroblasts (CAFs) and correlates with poor survival in PDAC patients. Targeting Pin1 using clinically available drugs induces complete elimination or sustained remissions of aggressive PDAC by synergizing with anti-PD-1 and gemcitabine in diverse model systems. Mechanistically, Pin1 drives the desmoplastic and immunosuppressive TME by acting on CAFs and induces lysosomal degradation of the PD-1 ligand PD-L1 and the gemcitabine transporter ENT1 in cancer cells, besides activating multiple cancer pathways. Thus, Pin1 inhibition simultaneously blocks multiple cancer pathways, disrupts the desmoplastic and immunosuppressive TME, and upregulates PD-L1 and ENT1, rendering PDAC eradicable by immunochemotherapy.

PubMed ID: 34388391 Exiting the NIEHS site

MeSH Terms: No MeSH terms associated with this publication

Back
to Top